MaxCyte Inc

NASDAQ:MXCT

Business Description

Sector

Health Care

Industry

Life Sciences Tools & Services

Headquarters

United States of America US

Employees

91

IPO date

Mar 29, 2016

MaxCyte sells cell-engineering tools that let scientists and drug makers move DNA, RNA, proteins, and other material into living cells. Its main product is an electroporation platform, along with disposable cartridges and related support services. The company’s customers are biotech and pharmaceutical firms, especially teams developing cell therapies and gene-edited medicines, as well as research labs that need reliable ways to modify cells.

The business makes money in two main ways: by selling instruments and consumables, and by licensing its platform to drug developers. The consumable cartridges create repeat business as customers keep using the system in their labs and manufacturing workflows. The licensing model is important because it ties MaxCyte to the success of partner programs without making the company itself a drug developer.

What makes MaxCyte different is that it sits at a key step in the cell-therapy value chain. It does not sell finished medicines; it sells the tools and know-how used to engineer the cells that become those medicines. That gives it a mix of equipment-style sales and recurring revenue from consumables and partner relationships, which is unusual for a life-science tools company.